Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic and even preclinical stages, possibly when potential treatments can best preserve cognitive function. We previously re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fagan, Anne M, Mintun, Mark A, Shah, Aarti R, Aldea, Patricia, Roe, Catherine M, Mach, Robert H, Marcus, Daniel, Morris, John C, Holtzman, David M
Format: Artigo
Idioma:Inglês
Publicat: WILEY-VCH Verlag 2009
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2806678/
https://ncbi.nlm.nih.gov/pubmed/20049742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/emmm.200900048
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars